XOMA ROYALTY

CORPORATE PRESENTATION

NASDAQ COMMON: XOMA
NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO

JUNE 2025

THE ROYALTY AGGREGATOR FOR BIOTECH COMPANIES

DISCLAIMERS

Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future potential monetization opportunities, active transactions with significant financial implications, collaborations poised for significant financial contribution, the ability of our partners and their licensees to successfully develop their pipeline programs, the productivity of acquired assets, our revenue and cashflow forecasts, upcoming internal milestones and value catalysts, our future cash needs, our strategy for value creation, and other statements that relate to future periods. These statements are not guarantees of future performance and undue reliance should not be placed on them. They are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market.

Potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filings on Form 10-K and Form 10-Q. Consider such risks carefully when considering XOMA Royalty's prospects. Any forward-looking statements represent XOMA Royalty's views only as of the date of this presentation and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by law.

NOTE: All references to “portfolio” in this presentation are to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in this presentation are to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates contained herein refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

XOMA ROYALTY – WHAT WE DO

The Biotech Royalty Aggregator

BUILDING THE XOMA ROYALTY BUSINESS

Scalable

BUSINESS MODEL

>$130M
since 2017

MILESTONES

100+
assets

+ New Deals

PIPELINE

REZOLUTE
ojemda™
gossamerbio
Castle Creek Biosciences
Takeda
AstraZeneca
darébio x2
Johnson & Johnson
AVEO ONCOLOGY an LG Chem company

1 undisclosed

PHASE 3 / REGISTRATION

VABYSMO
ojemda™
MIPLYFFA™
XACIATO™
IXINITY®
DSUVIA®

COMMERCIAL ROYALTIES

XOMA ROYALTY'S BUSINESS MODEL: THE COMPOUNDING EFFECT

↑ CASH RECEIPTS

— LOW EXPENSES

÷ LOW SHARE COUNT

HIGH EPS

SIGNIFICANT SHARE PRICE APPRECIATION

Path to Sustained Profitability



ojemda™ (tovorafenib)

Approved by FDA for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG), the most common form of childhood brain tumor

XOMA ROYALTY

- Acquired economics for $13.5M upfront in 2021
- Received $25.1M in milestones to date (additional $28M in potential milestones)
- Entitled to mid-single digit royalties on OJEMDA™ sales
- EMA has accepted MAA filing for review

MIPLYFFA™
arimoclomol capsules

Approved by FDA for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older

XOMA ROYALTY

- Acquired economics from LadRx for $5M upfront in 2023
- Potential to receive $52.6M in milestones
- Entitled to mid-single digit royalties on MIPLYFFA™ sales

XOMA ROYALTY IS DIFFERENTIATED



XOMA ROYALTY'S BUSINESS MODEL DIFFERENTIATION SHOULD ENHANCE VALUE CREATION



Visibility into future royalty portfolio differentiates XOMA ROYALTY from majority of royalty competitors

XOMA ROYALTY'S TIME IS NOW…

LIFE SCIENCES MARKETS ARE CHALLENGED…

EQUITY

↓ Volume

DEBT

↑ Cost

PARTNER

↓ Volume

M&A

↓ Volume

…CREATING OPPORTUNITY

ROYALTY MONETIZATION

↓ Equity Dilution

Unlock Latent Value

↑ Capital Efficiency

BASICS OF A XOMA ROYALTY MONETIZATION TRANSACTION

2 Royalty Monetization

1 License Agreement



XOMA ROYALTY'S IDEAL ROYALTY ASSET

HIGH ROYALTY POTENTIAL

High unmet need or clear clinical benefit over alternatives

LONG DURATION OF MARKET EXCLUSIVITY

Patent expiration or regulatory exclusivity

ESTABLISHED DEVELOPER / MARKETER

Assets partnered with reputable pharma / biopharma

MID- TO EARLY-STAGE CLINICAL ASSETS

Therapeutic area, modality agnostic

KEY ASSETS IN XOMA ROYALTY PORTFOLIO

ASSET	COMMERCIAL PARTNER	INDICATION	STAGE	CONSENSUS PEAK SALES [1]	ROYALTY %
VABYSMO®	Roche	Wet AMD / DME / RVO	Commercial	$7.3B	0.50%
OJEMDA™	Day One	pLGG	Commercial	$1.6B	Mid-single digit
MIPLYFFA™	Zevra	Niemann-Pick Type C	Commercial	$175M	Mid-single digit
XACIATO™	Organon	Bacterial infections	Commercial	NA	Low to high single digit
IXINITY®	Medexus	Hemophilia B	Commercial	$57M	5%
DSUVIA®	Talphera	Acute pain in supervised medical setting	Commercial	NA	75% of DoD sales
Ersodetug (RZ358)	Rezolute	cHI and tumor hyperinsulinism	Phase 3	$350M	High single digit / mid-teens
Seralutinib	Gossamer/Chiesi	PAH	Phase 3	NA	Low to mid-single digit
D-Fi (FCX-007)	Castle Creek	Dystrophic epidermolysis bullosa	Phase 3	NA	< 1.0%
Rilvegostomig	Astra-Zeneca	Solid Tumor(s)	Phase 3	NA	undisclosed
Mezagitamab	Takeda	ITP / IgAN	Phase 3	$1.0B	Mid-single digit
Ficlatuzumab	AVEO	HNSCC	Phase 3	NA	Low single digit
Ovaprene®	Bayer option	Contraceptive	Phase 3	NA	Low to mid-single
Cetrelimab	JNJ	Bladder Cancer	Phase 3	$2.1B	0.75%
Sildenafil cream, 3.6%	Daré	Female sexual arousal	Phase 3	NA	Low single

● = Acquired Assets

1. Peak sales estimates reflect Bloomberg consensus estimates of Commercial Partner as of May 10, 2024

XOMA ROYALTY DEAL & PORTFOLIO CONSTRUCTION

WELL-STRUCTURED

Recoup acquisition cost from milestone payments

RISK-MITIGATED



DIVERSIFIED

Indication	Mechanism
Modality	Stage

THE POWER OF THE XOMA ROYALTY MODEL

A Single Transaction[1] Can Deliver Significant Value for Shareholders

Dec 2023
ROYALTY-BACKED LOAN

$140M[3]

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

- Low Cost of Capital
- Tax Efficient
- Preserve NOLs
- Interest Expense ↓ Taxable Income
- Maintain Ownership & Upside

Oct 2021[1,2]
ACQUISITION

$14M

USE OF PROCEEDS: DELIVER ADDITIONAL SHAREHOLDER VALUE

Share Repurchase + **Royalty Acquisitions**

1. Acquired economics agreement from Affitech SA 2. Up to an additional $12M in sales-based milestones may be paid to Affitech SA 3. $130M initial draw; additional $10M if VABYSMO® royalties exceed certain threshold

ojemda™ (tovorafenib) + VOSAROXIN TRANSACTION:

$13.5M upfront to Viracta Therapeutics

	OJEMDA™	vosaroxin
Indication	Pediatric low-grade glioma	Myelodysplastic syndromes + AML
Milestone Potential	$54M Milestone Payments Received: $25.1M	$57M
Royalty Rate	Mid-single digit	High single digit
Clinical Stage	**FDA APPROVED[1] & COMMERCIAL** (Acquired in Ph2)	Phase 2
Partner	Day One BIOPHARMACEUTICALS	Denovo Biopharma

1. https://ir.dayonebio.com/news-releases/news-release-details/day-ones-ojemdatm-tovorafenib-receives-us-fda-accelerated

MIPLYFFA™ arimoclomol capsules + ALDOXORUBICIN TRANSACTION:

$6M to LadRx[1]

MIPLYFFA™ is a first-in-class therapy for NPC

	MIPLYFFA™	aldoxorubicin
Indication	Niemann-Pick Type C	Pancreatic Cancer
Milestone Potential	$52.6M	Mid-single digit percentage on out licensing economics
Royalty Rate	Mid-single digit	Low single digit
Clinical Stage	**FDA APPROVED[2] & COMMERCIAL** (Acquired pre-NDA resubmission)	Phase 2 (Aldox+Anktiva+PD-L1 t-hANK)
Partner	ZEVRA THERAPEUTICS	LadRx Corp

1. $5M upfront. $1M milestone paid to LadRx on FDA's acceptance of NDA resubmission. Up to an additional $5M in milestones may be paid to LadRx
2. https://investors.zevra.com/news-releases/news-release-details/zevra-therapeutics-miplyffatm-arimoclomol-receives-us-fda



DARÉ TRANSACTION:

$22M upfront to Daré for economic interest in 3 first-in-category assets[1]

	XACIATO™ (clindamycin phosphate) vaginal gel 2%	Ovaprene® (hormone-free monthly intravaginal contraceptive)	Sildenafil Cream, 3.6%
Indication	Bacterial vaginosis	Contraception	Female sexual arousal disorder
Milestone Potential[1]	$150M	$5M	
Royalty Rate[1]	Low to high single digit	Low to mid-single digit	Low single digit
Product Stage	**FDA APPROVED & COMMERCIAL** (Acquired post approval)	Phase 3	Phase 3-ready
Commercial Partner	ORGANON	BAYER[2]	

1. Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Daré.
2. Bayer holds exclusive option to license Ovaprene® for commercialization

IXINITY® TRANSACTION:

$9.6M upfront to Aptevo

Royalties through 1Q2035

	IXINITY®
Indication	Hemophilia B
Milestone Potential	undisclosed
Royalty Rate	5%
Clinical Stage	FDA approved & commercialized; sBLA approved in March 2024 for pediatric use <12 yo
Partner	MEDEXUS PHARMA

BIOINVENT TRANSACTION:

$20M upfront payment
$10M milestone payment on FDA approval in IgAN

Additional milestone & royalty economics in Takeda's mezagitamab

TWIST TRANSACTION:

$15M for economic interest in >60 assets



	Twist Biopharma Solutions
Milestone Potential	50% of milestone receipts
Royalty Rate	50% of low single digit
Clinical Stage	Early stage
Partner	30 partners

PULMOKINE ACQUISTION:

$20M upfront for economic interest in seralutinib, a Phase 3 asset

	Seralutinib
Indication	Pulmonary arterial hypertension (PAH) & pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Milestone Potential	Net up to $25M
Royalty Rate	Net low to mid-single digit
Product Stage	Phase 3
Commercial Partner	gossamerbio Chiesi

CASTLE CREEK BIOSCIENCE TRANSACTION:

$5M of a $75M syndicated royalty financing agreement

	D-Fi (FCX-007)
Indication	Dystrophic epidermolysis bullosa (DEB)
Royalty Rate	< 1 percent
Product Stage	Phase 3
Commercial Partner	Castle Creek Biosciences

KEY PORTFOLIO EVENTS ANTICIPATED in 2025 & 1H2026

Commercial Sales Ramps

VABYSMO

2024 Product Launches

ojemda™ (tovorafenib)

MIPLYFFA™ arimoclomol capsules

XACIATO™

Phase 3 Data Announcements

REZOLUTE

ersodetug (RZ358)

Congenital Hyperinsulinism (cHI)

gossamerbio

seralutinib

Pulmonary Arterial Hypertension

Phase 3 Clinical Starts

REZOLUTE

ersodetug

Hypoglycemia due to Tumor

Takeda

mezagitamab

FPFD* in ITP

FPFD* in IgAN

darébio

sildenafil cream, 3.6%

FPFD* in FSD

ADDITIONAL BUSINESS DEVELOPMENT

* FPFD: first patient first dose

BLUE OWL FINANCING – UP TO $140M

TERMS

$130M at close

9.875% interest

Secured only by VABYSMO royalties

STOCKHOLDER BENEFIT

Acquire assets for cash flow growth

Stock repurchases

XOMA retains long-term value of VABYSMO

WELL-STRUCTURED

Non-dilutive, non-recourse capital

Scaled $14M acquisition

Strategic partnership with Blue Owl

KINNATE TRANSACTION:

~$9.5M cash

added to XOMA's balance sheet for additional capital deployment & potential royalties on pipeline

	Kinnate Stockholders Receive	
Cash Amount (per share)	$2.5879	
Contingent Value Right (CVR)	85% of net proceeds	from out license or sale of Kinnate programs completed within 1 year of closing
	100% of net proceeds	from Kinnate's sale of exarafenib and pan-RAF inhibitor program to Pierre Fabre

FINANCIAL HIGHLIGHTS



>$130M in milestones since 2017

>$1B in potential milestones

6 assets generating royalty receipts

$46.3M in cash receipts during 2024

Stable Expense Base

XOMA ROYALTY'S STOCK REPURCHASE PROGRAM

Up to

$50 Million

through January 2, 2027

DRIVING SHAREHOLDER VALUE

THREE PUBLICLY TRADED OFFERINGS TO MEET THE NEEDS OF SPECIFIC INVESTORS

XOMA ROYALTY
Common Stock

XOMAP
Series A Cumulative Perpetual Preferred Stock
$25.00 par value

8.625% dividend paid quarterly

XOMAO
Series B Cumulative Perpetual Preferred Stock
$25.00 par value

8.375% dividend paid quarterly

WHO WE ARE

- **Leadership**
  - Owen Hughes, Chief Executive Officer
  - Brad Sitko, Chief Investment Officer
  - Tom Burns, Chief Financial Officer
- **Business Development Team**
- **Legal Team**
- **Finance Team**
- **Consultants**
  - Deal Sourcing
  - Scientific
  - Medical

Board of Directors

- **Jack Wyszomierski, Chairman**
  CFO of VWR International (retired)
- **Heather L. Franklin**
  Executive Chair of Blaze Bioscience
- **Natasha Hernday**
  CBO of Seagen (former)
- **Owen Hughes**
  CEO of XOMA
- **Barbara Kosacz**
  COO and GC of Kronos Bio (former)
- **Joe Limber**
  CEO of Secura Bio (former)
- **Matthew Perry**
  President at BVF Partners (former)

XOMA ROYALTY'S TIME IS NOW

INFLECTION POINT FORTHCOMING

EFFICIENT BUSINESS MODEL

COMPETITIVE DIFFERENTIATION

ROYALTIES TO DRIVE SHAREHOLDER RETURNS

Enabling Today's Science to Be Tomorrow's Cures

XOMA ROYALTY

CORPORATE PRESENTATION

NASDAQ COMMON: XOMA
NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO

JUNE 2025

THE ROYALTY AGGREGATOR FOR BIOTECH COMPANIES